{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T10:13:54Z","timestamp":1760955234078},"reference-count":27,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biochimie"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1016\/j.biochi.2010.06.010","type":"journal-article","created":{"date-parts":[[2010,6,21]],"date-time":"2010-06-21T00:26:53Z","timestamp":1277080013000},"page":"1315-1320","source":"Crossref","is-referenced-by-count":12,"title":["Development and preclinical evaluation of a new F(ab\u2032)2 antitoxin against botulinum neurotoxin serotype A"],"prefix":"10.1016","volume":"92","author":[{"given":"Yun-Zhou","family":"Yu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu-Ming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Bing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heng-Qi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui-Lin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Wei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Bo","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Yuan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei-Tang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Wei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.biochi.2010.06.010_bib1","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0968-0004(02)02177-1","article-title":"botulinum and tetanus neurotoxtins: structure, function and therapeutic utility","volume":"27","author":"Turton","year":"2002","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.biochi.2010.06.010_bib2","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1152\/physrev.2000.80.2.717","article-title":"Neurotoxins affecting neuroexocytosis","volume":"80","author":"Schiavo","year":"2000","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.biochi.2010.06.010_bib3","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/DMP.0b013e318158c5fd","article-title":"Botulism: cause, effects, diagnosis, clinical and laboratory identification, and treatment modalities","volume":"1","author":"Dembek","year":"2007","journal-title":"Disaster Med. Public Health Prep."},{"key":"10.1016\/j.biochi.2010.06.010_bib4","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1001\/jama.285.8.1059","article-title":"Working group on civilian biodefense, botulinum toxin as a biological weapon","volume":"285","author":"Arnon","year":"2001","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.biochi.2010.06.010_bib5","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00013542-200101000-00004","article-title":"Antitoxin therapy for botulinum intoxication","volume":"12","author":"Mayer","year":"2001","journal-title":"Rew. Med. Microbiol."},{"key":"10.1016\/j.biochi.2010.06.010_bib6","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.toxicon.2006.05.007","article-title":"Botulinum type A toxin neutralisation by specific IgG and its fragments: a comparison of mouse systemic toxicity and local flaccid paralysis assays","volume":"48","author":"Jones","year":"2006","journal-title":"Toxicon"},{"key":"10.1016\/j.biochi.2010.06.010_bib7","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0300-9084(00)01173-1","article-title":"Development of vaccines for prevention of botulism","volume":"82","author":"Byrne","year":"2000","journal-title":"Biochimie"},{"key":"10.1016\/j.biochi.2010.06.010_bib8","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.addr.2005.01.016","article-title":"Production of vaccines against leading biowarfare toxins can utilize DNA scientific technology","volume":"57","author":"Middlebrook","year":"2005","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.biochi.2010.06.010_bib9","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1128\/IAI.63.7.2738-2742.1995","article-title":"Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli","volume":"63","author":"Clayton","year":"1995","journal-title":"Infect. Immun."},{"key":"10.1016\/j.biochi.2010.06.010_bib10","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.febslet.2004.06.094","article-title":"Interaction between the two subdomains of the C-terminal part of the botulinum neurotoxin A is essential for the generation of protective antibodies","volume":"572","author":"Tavallaie","year":"2004","journal-title":"FEBS Lett."},{"key":"10.1016\/j.biochi.2010.06.010_bib11","doi-asserted-by":"crossref","first-page":"6998","DOI":"10.1128\/IAI.73.10.6998-7005.2005","article-title":"Characterization of the antibody response to the receptor binding domain of botulinum neurotoxin serotypes A and E","volume":"73","author":"Baldwin","year":"2005","journal-title":"Infect. Immun."},{"key":"10.1016\/j.biochi.2010.06.010_bib12","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1128\/IAI.01893-06","article-title":"Trivalent vaccine against botulinum toxin serotypes A, B, and E that can be administered by the mucosal route","volume":"75","author":"Ravichandran","year":"2007","journal-title":"Infect. Immun."},{"key":"10.1016\/j.biochi.2010.06.010_bib13","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1016\/j.vaccine.2009.02.091","article-title":"The recombinant Hc subunit of Clostridium botulinum neurotoxin serotype A is an effective botulism vaccine candidate","volume":"27","author":"Yu","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.biochi.2010.06.010_bib14","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1128\/CVI.00239-08","article-title":"Evaluation of a recombinant Hc of Clostridium botulinum neurotoxin serotype F as an effective subunit vaccine","volume":"15","author":"Yu","year":"2008","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.biochi.2010.06.010_bib15","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1128\/IAI.66.10.4817-4822.1998","article-title":"Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate","volume":"66","author":"Byrne","year":"1998","journal-title":"Infect. Immun."},{"key":"10.1016\/j.biochi.2010.06.010_bib16","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/S0041-0101(98)00146-9","article-title":"Development of recombinant vaccines for botulinum toxin","volume":"36","author":"Smith","year":"1998","journal-title":"Toxicon"},{"key":"10.1016\/j.biochi.2010.06.010_bib17","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1475-2859-4-33","article-title":"Recombinant production of bacterial toxins and their derivatives in the methylotrophic yeast Pichia pastoris","volume":"4","author":"Gurkan","year":"2005","journal-title":"Microb. Cell Fact."},{"key":"10.1016\/j.biochi.2010.06.010_bib18","doi-asserted-by":"crossref","first-page":"5661","DOI":"10.1016\/j.vaccine.2009.07.021","article-title":"Immune response of horses to vaccination with the recombinant Hc domain of botulinum neurotoxin types C and D","volume":"27","author":"Stahl","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.biochi.2010.06.010_bib19","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1615\/CritRevImmunol.v27.i4.20","article-title":"Botulinum neurotoxin vaccines: past, present, and future","volume":"27","author":"Smith","year":"2007","journal-title":"Crit. Rev. Immunol."},{"key":"10.1016\/j.biochi.2010.06.010_bib20","series-title":"Pharmacopoeia of the people\u2018s Republic of China (Volume III), Appendix XII H: The Potency Assay of Botulinum Antitoxin","author":"Chinese Pharmacopoeia Commission","year":"2005"},{"key":"10.1016\/j.biochi.2010.06.010_bib21","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/0002-9343(84)90988-4","article-title":"Equine antitoxin use and other factors that predict outcome in type A foodborne botulism","volume":"76","author":"Tacket","year":"1984","journal-title":"Am. J. Med."},{"key":"10.1016\/j.biochi.2010.06.010_bib22","first-page":"89","article-title":"Immunodiagnosis and immunotherapy of tetanus and botulinum neurotoxins","volume":"95","author":"Middlebrook","year":"1995","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.biochi.2010.06.010_bib23","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1001\/jama.278.5.399","article-title":"Clinical recognition and management of patients exposed to biological warfare agents","volume":"278","author":"Franz","year":"1997","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.biochi.2010.06.010_bib24","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1002\/(SICI)1099-1263(199912)19:1+<S35::AID-JAT612>3.0.CO;2-9","article-title":"Protection against botulinum toxins provided by passive immunization with botulinum human immune globulin: evaluation using an inhalation model","volume":"19","author":"Gelzleichter","year":"1999","journal-title":"J. Appl. Toxicol."},{"key":"10.1016\/j.biochi.2010.06.010_bib25","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/0041-0101(96)00070-0","article-title":"Therapeutic botulinum type A toxin: factors affecting potency","volume":"34","author":"McLellan","year":"1996","journal-title":"Toxicon"},{"key":"10.1016\/j.biochi.2010.06.010_bib26","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/0002-9343(80)90469-6","article-title":"Hypersensitivity reactions associated with botulinal antitoxin","volume":"69","author":"Black","year":"1980","journal-title":"Am. J. Med."},{"key":"10.1016\/j.biochi.2010.06.010_bib27","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1081\/IPH-120024507","article-title":"Anti-immunoglobulin responses to IgG, F(ab\u2032)2, and Fab botulinum antitoxins in mice","volume":"25","author":"Mayers","year":"2003","journal-title":"Immunopharmacol. Immunotoxicol."}],"container-title":["Biochimie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300908410002245?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300908410002245?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T23:20:01Z","timestamp":1591399201000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0300908410002245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["S0300908410002245"],"URL":"https:\/\/doi.org\/10.1016\/j.biochi.2010.06.010","relation":{},"ISSN":["0300-9084"],"issn-type":[{"value":"0300-9084","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]}}}